New Oral Anticoagulants. Their Role in Stroke Prevention in High-Risk Patients with Atrial Fibrillation

Sunita J. Ferns, Gerald V. Naccarelli

Research output: Contribution to journalReview article

2 Scopus citations

Abstract

Based on efficacy, safety, and ease of use, novel oral anticoagulants will likely replace VKAs for many if not most patients with atrial fibrillation. Novel anticoagulants have a lower rate of intracranial hemorrhage compared with vitamin K antagonists. The incidence of other life-threatening bleeds is similar if not lower. Dose adjustments need to be made based on renal function and advanced age. There is at present a need for an antidote for these new drugs.

Original languageEnglish (US)
Pages (from-to)759-780
Number of pages22
JournalMedical Clinics of North America
Volume99
Issue number4
DOIs
StatePublished - Jul 1 2015

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint Dive into the research topics of 'New Oral Anticoagulants. Their Role in Stroke Prevention in High-Risk Patients with Atrial Fibrillation'. Together they form a unique fingerprint.

  • Cite this